3504

## Final Skeptic Assessment

### Addressed Concerns

The theorist's rebuttal effectively clarifies several points. The iPSC evidence (Sidransky et al., 2019) partially addresses causal direction concerns by demonstrating human-relevant phenotypes absent in rodents—though this strengthens plausibility rather than proving in vivo causality. The reframing of neuromelanin vulnerability around iron-neuromelanin synergy is mechanistically coherent. The isradipine trial reframing is valid: calcium antagonism may test an upstream, non-overlapping pathway.

### Unresolved Concerns

**Three critical gaps persist:**

1. **Regional substrate validation remains correlative.** The Steger et al. phospho-RAB10 elevation in PD SNc tissue does not establish directionality—RAB10 hyperphosphorylation could result from compensatory kinase activation secondary to another primary insult.

2. **Striatal vulnerability undermines cell-type specificity.** The original model predicted resilience in striatal interneurons. Yet Vilas et al. (2022) documented clear striatal dysfunction in LRRK2 carriers via imaging. If lysosomal membrane dynamics are the mechanistic core, why do striatal neurons—which the model predicts should be spared—show pathology?

3. **The compensatory exhaustion concession is unfalsifiable.** By acknowledging TFEB exhaustion as a late-onset mechanism, the theorist introduces a variable that is difficult to test prospectively. Any negative finding can be attributed to "insufficient time for exhaustion to manifest."

### Paper Still Undermining the Hypothesis

Herzig et al. (2011; PMID: 21768383) remains unaddressed at the systems level: G2019S knock-in mice expressing the mutation throughout life show minimal SNc cell loss despite documented lysosomal dysfunction. This dissociation between molecular phenotype and neurodegeneration is the core unresolved tension.

### Final Confidence Score: **0.52**

### Key Remaining Gap

The fundamental gap is temporal: the hypothesis requires a cascade from LRRK2 dysfunction → lysosomal membrane impairment → selective neuronal death spanning decades in humans. No current model—whether mouse, iPSC, or post-mortem tissue—captures this progression mechanistically. Without longitudinal human biomarker data linking early lysosomal dysfunction to later neurodegeneration, therapeutic confidence remains constrained.

["PMID:27103068", "PMID:25937444", "PMID:20739880", "PMID:16478028", "PMID:25897030", "PMID:19602543", "PMID:21768383", "PMID:35124753", "PMID:32869926", "PMID:21342605", "PMID:22506239", "DOI:10.1016/j.nbd.2015.03.011).", "PMID:34158340", "PMID:25882682", "PMID:30774578", "PMID:18497242"]